Cyclizine

Motion sickness, a vestibular dysfunction disease with high incidence in travel scenarios, has long had clinical pain points of slow onset and obvious side effect of drowsiness. The advent of cyclizine provides a better option for the intervention of such diseases. As a first-generation piperazine H1 antihistamine, it can block H1 receptors and M cholinergic receptors in the central nervous system, inhibit the excitability of vestibular nerves, and reduce the signal transduction of the vomiting center at the same time. It is mainly used to prevent and treat nausea and vomiting caused by motion sickness, sea sickness and airsickness, and can also be used for the symptomatic relief of postoperative, radiotherapy-induced and drug-induced vomiting. Its applicable population covers adults and children over 6 years old, and it is a first-line drug for motion sickness recommended by multiple guidelines worldwide.

At present, the global market size of cyclizine preparations is about USD 230 million, and the compound annual growth rate from 2023 to 2029 is expected to remain at 4.1%. The growth momentum mainly comes from the recovery of travel demand and the expansion of perioperative antiemetic medication scenarios. In terms of the competitive landscape, the European and American markets are mainly supplied by both original research and generic pharmaceutical enterprises. In the domestic market, the cyclizine preparations currently used clinically are still mainly imported varieties, the declaration of domestic generic drugs is still in the initial stage, the supply gap of API is large, and no enterprise has been included in the scope of national centralized procurement varieties.

The original research enterprise of cyclizine is Pfizer, with the original brand name Marezine, and the core compound patent expired globally in 1988. The currently marketed original dosage form is mainly tablet, with the specification of 50mg, and its oral tablet has been included in the FDA Reference Listed Drug Catalog. In China, there is no approved cyclizine preparation product on the market at present, and there is no public cyclizine API registration number in A status or I status on the CDE API registration platform for the time being, and the generic drug development of relevant varieties is in the early stage. (Data as of July 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for cyclizine API. Most products are in regular stock, and orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for all stages of generic drug research and development and quality research.